Ottawa’s TD Place will now have to wait until 2022 to host professional rugby league
Ottawa’s TD Place will now have to wait until 2022 to host professional rugby league
The agreement reinforces the existing collaboration, which was initiated in 2017 between the two companies and builds on Miral’s strategy to partner with leading global brands as a part of its long-term vision for Yas Island. Miral first appointed Hilton back in 2017 to operate and manage the Hilton Abu Dhabi Yas Island Hotel, currently under construction on Yas Bay at the southern end of Yas Island.Yas Island is also home to Ferrari World, considered the World’s Leading Theme Park by the World Travel Awards, while Warner Bros. World Abu Dhabi is recognised as the Middle East’s Leading Tourist Attraction. Carlos Khneisser, vice president, development, MEA at Hilton, said: “We are proud to be partnering with Miral on these two new hotels, which will see us introduce two new brands to Abu Dhabi. The WB Abu Dhabi, which will be part of Hilton’s Curio Collection, is a magnificent example of the sort of unique guest experiences we look for with Curio Collection, while DoubleTree by Hilton Yas Island Residences continues the successful growth of this brand in the UAE. “Miral has a clear vision to develop Yas Island into a global destination and we look forward to being a part of this transformation.”The WB Abu Dhabi, part of Hilton’s Curio Collection, is set to become a unique hotel adjacent to the award-winning Warner Bros. World Abu Dhabi theme park. The hotel is currently more than 75 per cent complete and once finished will allow guests to experience recognizable characters from across Warner Bros.’ iconic collection of film, television and comics. Set to open in 2021, the hotel will feature 257 rooms over eight levels, with guests able to access a range of amenities, including signature WB restaurants, WB store, a premier spa and fitness club, kids club, family pool and an exclusive rooftop pool overlooking Yas Island’s distinctive skyline.DoubleTree by Hilton – Yas Island Residences currently stands at more than 75 per cent complete and is due for completion in 2021. The property provides a variety of options that accommodate different needs, especially larger families looking for more space and in-room amenities.A total of 156 units offer guests a range of studio, one-, two- and three-bedroom accommodation. Full amenities will include in-room kitchenettes, gym, pool and a variety of recreation facilities.The new hotels are all within walking distance from Warner Bros. World Abu Dhabi and Yas Waterworld – the World’s Leading Waterpark – and are in close proximity to Yas Island’s other attractions and experiences, including Clymb Abu Dhabi and numerous world-class food and beverage outlets on the Island. Signed by Mohamed Abdalla Alzaabi, chief executive of Miral, and Jochem-Jan Sleiffer, president for Hilton in the Middle East, Africa and Turkey, the agreement brings the two brand to Abu Dhabi for the first time.The deal also demonstrates a commitment from Miral to bringing exclusive hospitality venues to Yas Island, which further positions it as one of the top global destinations for entertainment, leisure and business.Yas Island is already considered the World’s Leading Tourism Development Project by voters at the World Travel Awards. – Advertisement – NewerTravellers from Denmark barred from entry to UK OlderW Dubai – the Palm offers new fitness staycation – Advertisement – Miral has appointed Hilton to bring two new and unique hospitality offerings to Yas Island, while it invests AED627 million (£130 million) in their development. The WB Abu Dhabi, first Warner Bros. branded hotel in the world, will be operated and managed by Hilton under its upper-upscale Curio Collection by Hilton brand, while the serviced residences will be managed by DoubleTree by Hilton.- Advertisement – BR Kiran, chief portfolio officer at Miral, said: “Hilton is a globally recognised partner, and we are honoured to be partnering with them to bring the Curio Collection by Hilton and DoubleTree by Hilton brands to Abu Dhabi for the first time. “This supports our strategy and vision of creating unforgettable experiences for every guest on Yas Island, while increasing the diversity of hospitality options available to them. “We are confident that residents and visitors alike will welcome the diverse and flexible range of new accommodation options, while enjoying the unmatched experiences and unique attractions available to them on Yas Island.”- Advertisement –
The closest constituency, not surprisingly, was the 1st District along the coast, where Trump’s moved downward from 53-40 to only 52-46. This shift to the left, though, wasn’t quite enough for freshman Democratic Rep. Joe Cunningham, who lost reelection 51-49 against Republican Nancy Mace.Trump carried his other five seats by double digits. The closest was the 2nd District in the Augusta and Columbia suburbs, which supported him 56-39 in 2016 but by a smaller 55-44. Democrats hoped before Election Day that veteran Rep. Joe Wilson, a Republican who infamously screamed “You lie!” at Barack Obama during a congressional address in 2009, could be vulnerable there against well-funded Democrat Adair Ford Boroughs, but Wilson won by a comparable 56-43. The 6th District, meanwhile, moved from 67-30 Clinton to 67-32 Biden.- Advertisement – – Advertisement –
– Advertisement –
Norway have said their final Nations League group game against Austria on Wednesday will go ahead despite Sunday’s match against Romania being cancelled due to coronavirus restrictions.The Norway squad was on their way to the airport to catch a chartered flight to Bucharest when authorities told them the journey would breach the country’s stringent coronavirus measures after a player in the squad had tested positive for the virus.- Advertisement – – Advertisement – Austria, who beat Northern Ireland 2-1 on Sunday, top Group 1 in League B on 12 points ahead of Norway, who are second on nine points.The Norwegians are likely to be handed a 3-0 defeat by UEFA after their no-show in Romania.If that is the case then Northern Ireland would be consigned to the bottom of the table and relegation from League B.- Advertisement – It meant the players originally called up are unable to play and were told the self-isolate, leaving the country’s football association scrambling to form a new squad for Wednesday’s group decider against Austria.In a statement, the Norwegian Football Federation said the game against Austria would now go ahead and a new squad coached by U21 boss Leif Gunnar Smerud would be presented at a press conference on Monday morning.The players selected will fly to Oslo and observe a strict quarantine at an airport hotel before departing for the game, the NFF explained.- Advertisement – “These have been demanding assessments, but we are now happy that the match can be played, both sportingly and out of consideration for our obligations to UEFA and the tournament we participate in,” NFF general secretary Pal Bjerketvedt said.Winning the group would mean Norway gets promoted to the top flight of the Nations League and provide another possible route to the World Cup finals, which they have not qualified for since 1998.
Jan 26, 2005 (CIDRAP News) – The idea of stopping an emerging influenza pandemic would have seemed ridiculous until a few years ago, but today the world just might have a chance to do that, according to two flu experts who published opinion pieces this week.The World Health Organization (WHO) and many others have been warning frequently that the H5N1 avian influenza virus circulating in Southeast Asia could launch a human flu pandemic. The virus has infected more than 50 people in Vietnam and Thailand and killed most of them, but it has not yet found a way to spread easily from person to person.Writing in the New England Journal of Medicine, Klaus Stohr, head of the WHO’s global influenza program, says the virus could acquire this ability suddenly by mixing with a human-adapted flu virus. Alternatively, he speculates, the virus might develop this ability more gradually by incrementally adapting to human hosts.If the latter happens and is detected, Stohr writes, “Its detection could open an opportunity to intervene with antiviral drugs or a vaccine and thus forestall international spread or even eliminate a virus with low transmissibility.”Though it is an attractive option, no attempt has ever been made to interrupt the transmission of an influenza virus; the results of such an enormous and costly undertaking remain uncertain. The option deserves further investigation, however, particularly when viewed against the profound effect a delay in global spread and a flattening of the peak in disease prevalence could have during the initial phase of a pandemic.”One potential way to arrest an emerging flu pandemic would be to quickly treat patients and their contacts with the antiviral drug oseltamivir, which is known to inhibit H5N1 viruses, according to Arnold S. Monto, MD, professor of epidemiology at the University of Michigan in Ann Arbor.In a separate commentary piece in NEJM, Monto writes, “It might be possible to achieve local control of an incipient outbreak among humans by using oseltamivir for prophylaxis in the contacts of patients as well as for treatment in the infected persons themselves. Treatment of patients alone would not prevent further spread, but it might reduce the shedding of the virus and would, in any event, be required for ethical reasons.”Both Stohr and Monto acknowledge that such an effort would face big obstacles. “A mobile stockpile of the drug would have to exist and be made available in the affected country,” writes Monto. A number of developed countries are already stockpiling oseltamivir against the threat of a pandemic. Hence, stockpiling the drug in countries now affected by avian flu could require diverting supplies from other national stockpiles. “However, this diversion must happen,” he states.Monto adds that the idea of trying to stop a pandemic at its source “would have been considered laughable just a few years ago—but that was before SARS [severe acute respiratory syndrome] transmission was controlled by public health measures.” Though no effective treatment for SARS has yet been developed, the disease was controlled through such standard measures as isolating patients, quarantining exposed people, and screening travelers.But heading off an H5N1 flu pandemic with vaccination and antiviral drugs probably isn’t possible at this point, in the view of infectious disease authority Michael T. Osterholm, PhD, MPH.It takes days to confirm a case of H5N1 avian flu, and treating the patient and his or her contacts with oseltamivir during that time would be a needless use of the drug if the illness turned out to be something else, he told CIDRAP News. “You wouldn’t want to use oseltamivir for everyone coming in with a flu-like illness, because you would quickly exhaust the world supply,” he said.Osterholm, who is director of the University of Minnesota Center for Infectious Disease Research and Policy, publisher of this Web site, expressed doubt about the practicability of finding and treating the contacts of case-patients in time to stop transmission of H5N1. “I think the movement of humans today is so dynamic that we have a very leaky system,” he said.As for immunization, some H5N1 vaccines are under development, but no one knows whether they would work against an emerging pandemic strain, he said. “We don’t have a pandemic strain of vaccine yet, and we don’t have any idea whether any of the vaccines to date would be efficacious.”Osterholm said he currently knows of no other practical ways to stave off a flu pandemic, should the H5N1 virus soon become capable of spreading. “Once we have sustained transmission in humans, all the science, experience, and my gut tell me we’re going to be dealing with a worldwide pandemic,” he said. He suggested that leaders should focus on finding ways to keep governments operating and protect infrastructures in the face of a pandemic.Stohr writes that it is a mystery why the H5N1 virus hasn’t already evolved into a pandemic form by “reassorting” with human flu viruses, given the large numbers of Asian poultry workers and healthcare workers already exposed to it. He says the explanation could be sheer luck, or it could be “that reassortment has occurred but has resulted in viruses that are not viable, not pathogenic, or not more easily transmitted among humans than H5N1 already is.”The only way to answer the question is to produce reassortment in a secure laboratory, and one laboratory is doing that, Stohr writes. He doesn’t name the lab, but the US Centers for Disease Control and Prevention recently revealed that it would conduct reassortment experiments. Stohr’s article says this research may not be completed before the end of this year.See also:Stohr K. Avian influenza and pandemics—research needs and opportunities. N Engl J Med 2005;352(4):405-7http://www.nejm.org/doi/full/10.1056/NEJMe048344Monto AS. The threat of an avian influenza pandemic. N Engl J Med 2005;352(4):323-5http://www.nejm.org/doi/full/10.1056/NEJMp048343CIDRAP News story, “CDC to mix avian, human flu viruses in pandemic study”http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/news/jan1404hybrids.html
Sept 1, 2006 (CIDRAP News) – The nation’s largest public health organization sounded an alarm this week about the public health workforce, citing a current shortage and projecting that the profession could lose up to half of its workers over the next few years.The American Public Health Association (APHA) outlines the problem in a report titled “The Public Health Workforce Shortage: Left Unchecked, Will We Be Protected?” It was released on the eve of the first anniversary of Hurricane Katrina.In a press release, the APHA called for immediate action to reverse the shortages, which it said could leave great numbers of Americans vulnerable to a number of health threats.The report says the number of public health workers decreased from 220 per 100,000 Americans in 1980 to 158 per 100,000 in 2000.”Our emerging public health workforce crisis comes at a time when Americans are facing a host of risks to their health and safety, from bioterrorism to pandemic influenza and environmental disasters,” said Georges C. Benjamin, MD, executive director of the APHA. “At the same time, we risk losing ground on responding to ongoing health problems such as obesity, heart disease and cancer.”Federal funding to recruit and train public health workers must increase dramatically, and states should evaluate their public health workforce needs and establish development and training programs, Benjamin said. “Medical devices and disease tracking instruments are ineffectual without adequately educated and trained workers,” he said.The APHA says that in the next few years, state and federal public health agencies could lose up to half of their workers to retirement, the private sector, and other opportunities. A study from the Association of State and Territorial Health Officials and the Council of State Governments found that the average age of state public health workers is 47 years, 7 years older than the national average for all occupations. Current vacancy rates are as high as 20% in some agencies, and annual turnover rates have reached 14% in some parts of the country.The most severe shortages were found in epidemiology, nursing, laboratory science, and environmental health, the APHA says.Although the public health workforce has become more diverse in the past 30 years, there is room for improvement in that area, the report says. Minority group members make up about 25% of the US population but only about 10% of people in the health professions. Increasing diversity in public health work would help reduce many health disparities, because the profession could respond better to the needs of minority populations, according to the report.The APHA urges several strategies to stem the workforce shortage:Establish federally funded scholarship and loan repayment programs modeled after those outlined in the Public Health Preparedness Workforce Development Act, introduced by Sen. Chuck Hagel, R-Neb., and Sen. Richard Durbin, D-Ill.Renew investment in federal programs that address the shortage of medical personnel in underserved areas to shore up and diversify public health professions such as epidemiology, environmental health, maternal and child health, and nursingIncrease financial support for the public health infrastructureEnhance leadership development programsExpand internship and fellowship programs in agencies such as the Centers for Disease Control and Prevention and the National Institutes of Health.
Mar 23, 2007 (CIDRAP News) – Indications today are that Thailand will continue to share H5N1 avian influenza viruses with the World Health Organization (WHO), contrary to a news report yesterday.Bloomberg News reported yesterday that Thailand would restrict access to its H5N1 viruses, and CIDRAP News passed along that report. But a senior Thai health official said Thailand had no plans to withhold samples, according to a Reuters report published yesterday.In addition, WHO spokesman Dick Thompson in Geneva told CIDRAP News today that Thailand has not signaled any intention to withhold samples. “We have received no official information that the situation relating to sharing of samples from Thailand has changed,” Thompson said via e-mail.Thai officials quoted by both Bloomberg and Reuters said Thailand shared Indonesia’s concern about access to vaccines based on samples collected in the country. Indonesia revealed in early February that it had stopped sharing H5N1 samples with the WHO out of concern that high cost would put any vaccines made using the samples out of reach for Indonesia.Bloomberg’s report cited comments by Public Health Minister Mongkol Na Songkha. The Reuters story quoted the minister’s senior adviser, Suwit Wibulpolprasert, who, when asked if Thailand planned to withhold samples, said, “No, never. Definitely not.”Scientists regard access to recent H5N1 virus isolates as essential for monitoring the virus’s evolution and developing vaccines against it.
Jun 20, 2007 (CIDRAP News) – The company that markets oseltamivir (Tamiflu) in Japan has announced it will launch new studies to explore whether the antiviral drug contributes to adverse psychiatric and neurologic events in teenagers.Meanwhile, experts at an international influenza conference this week in Toronto reported some progress in the quest for new types of antiviral drugs for flu patients, and Vietnam said it was ready to launch a trial of a locally made human vaccine for H5N1 avian flu.Teen deaths prompt new studiesIn aJun 18 news release, Chugai Pharmaceutical Co. said it has received several reports of serious psychiatric or neurologic events since oseltamivir’s 2001 launch in Japan. Though no link between the adverse events and the drug was established, in May 2004 Chugai added information about the reported symptoms to its packing inserts. The company imports oseltamivir from Roche and markets it in Japan.Four months ago Chugai said it received a report of two teenage flu patients who fell to their deaths after taking oseltamivir, the press release said. After the accidents, Japan’s health ministry warned that children with the flu could show adverse behavioral effects, whether or not they were receiving oseltamivir, and advised doctors to avoid prescribing it to teenagers.Oseltamivir, a neuraminidase inhibitor, is used for both treatment and prevention. Because world health experts regard it as the best available drug for combating a potential pandemic flu strain, the United States and numerous other countries are stockpiling it.Chugai said it is examining adverse event reports to determine if any patterns emerge in the patient histories, timing of the drug, or onset of any abnormal behaviors.Also, following Japanese health ministry proposals, Chugai and Roche will immediately conduct new research on the drug’s safety. In preclinical trials, the companies will use rats to gauge the drug’s effects on the brain, the press release said. A clinical research arm of the studies will assess the effect of oseltamivir on subjects’ sleep and look at transport of the drug to the cerebrospinal fluid.Chugai also will proceed with epidemiologic studies of patients treated with oseltamivir, to examine what other drugs they take, their flu symptoms and clinical course, and their medical history. The company said its goal is to use the studies to guide safety measures for the next flu season.A 2006 report by the US Food and Drug Administration concluded it was unclear if neuropsychiatric events in those treated with oseltamivir were related only to the drug, only to the flu, or to both.In previous statements, Roche has said that clinical trials in the United States and Japan showed similar rates of psychiatric symptoms in children with flu who took oseltamivir and in peers who didn’t take it. The company also said US health insurance data showed that patients treated with the drug had a lower likelihood of events such as delirium, confusion, and hallucination than patients who were not treated.Researchers discuss what’s on the antiviral horizonIn presentations at the Options for the Control of Influenza Conference in Toronto yesterday, researchers offered glimpses of potential new antiviral medications, according to a Jun 19 Canadian Press (CP) report.Frederick Hayden, MD, an antiviral expert with the World Health Organization (WHO), said work on new classes of antivirals drugs may eventually make the world less vulnerable to flu than it is now, with only four drugs in two classes available.”The pipeline is not full, but it’s certainly more robust than it was some years ago,” Hayden told CP.Later this week at the conference, researchers will present their work on a new drug, currently called T705, which targets the polymerase protein, a new target for flu antivirals, the CP story said. Hayden said phase 2 clinical trials of the drug will begin later this year.Meanwhile, researchers from the Institute for Cellular and Molecular Biology at the University of Texas at Austin have identified a drug target on the flu virus’s nonstructural protein, the CP report said. Robert Krug, a researcher at the institute, said the lab has screened molecules that could strike the target and have come up with a good “hit,” though development of a drug could take 5 years, even if the work goes smoothly.An advantage of the nonstructural protein target is that it is the same in different virus strains, unlike other parts of the virus, the story said.Vietnam to launch trial of H5N1 vaccineHealth officials in Vietnam said the country was set to launch the first human trial of its own H5N1 avian flu vaccine, Agence France-Presse (AFP) reported today.Nguyen Tran Hien, director of the National Institute of Hygiene and Epidemiology (NIHE) in Hanoi, told AFP the trial will begin as early as July, with the health ministry’s approval, and should be finished next year. He said researchers will enroll 20 to 30 volunteers for the study.Experts from the United States will provide Vietnam with technical assistance to develop the vaccine, US health attaché Michael Iademarco told AFP. The United States provided $1 million to Vabiotech, a company with ties to NIHE, apparently to support the development of the vaccine, Iademarco said.In the past few weeks, Vietnam has reported five human cases of H5N1 avian flu, with one death, and since early May, bird outbreaks have been reported in 16 of the country’s 59 provinces. The World Health Organization has not yet confirmed the recent human cases in Vietnam, so the official case count for now remains at 93 cases and 42 deaths.See also:Jun 18 Chugai press releaseMar 21 CIDRAP News story “Japan warns against Tamiflu use in teens”